Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

More documents

Recommendations

Info

110Annual Report on Lymphatic Filariasis 2003Chapter 3 Programme implementationFigure 3.184 Outcomes and planning 2001-2008No. of IUs64202001200220032004Planned pop. coverage200520062007Figure 3.186 Geographical coverage% of at-risk population covered10075502501.6220019.72002No. IUs20086050403020100Pop. reported to haveingested drugs13.42003million peopleThe Ministry of Health initiated the LF elimination programmein 2001 with assistance from AusAID and WHOand scaled up to cover four districts in 2002 with fundingassistance from the Liverpool LF Support Centre andWHO, plus albendazole donated by GSK. The supplies ofDEC were provided by WHO through a grant from theBill and Melinda Gates Foundation.Figure 3.185 LF at-risk populationPopulation in millions160120804001009080Total pop.120.4 M95.5At-risk pop.49.9 MFigure 3.187 MDA reported coverage93.992.2%70Figure 3.188 IUs with reported coverage >65%60100100 100 100502001200220038060%4020Figure 3.189 Updated mapping statusTotal: 64 IUs41 IUs — 23 IUs0200120022003Uncertain Non-endemic Endemic
INDIA111Endemicity statusEndemicNon-endemicUncertainAnnual Report on Lymphatic Filariasis 2003LF represents a major vector-borne public health problemto India’s population of approximately 1049 million:more than 454 million are now considered to be at risk.The disease has been known in the country for millennia,the earliest-known description of symptoms datingback to 600 BC. The largest at-risk population is situatedin Uttar Pradesh, followed by Bihar and Andhra Pradesh.The number of LF clinical manifestations is estimated atmore than 20.8 million cases.The administrative division designated as an IU is thedistrict. The mapping of LF is based on extensive historicaldata which showed that 261 out of 616 districts areconsidered LF-endemic.the programme. Initially, control measures for filariasiswere restricted to urban areas. In 1997, the NationalFilariasis Control Programme piloted a revised strategybased on a single annual dose of DEC that targeted an atriskpopulation of 40 million in 13 IUs. The first round ofMDA using albendazole plus DEC began in 2001 in nineIUs (six in Tamil Nadu, two in Orissa and one in Kerala).In 2002, 23.8 million in 11 IUs (six in Tamil Nadu, four inOrissa and one in Kerala) were targeted, with a reportedcoverage of 88.2% (range 67.3% to 97.3%). In 2003, sevenIUs and 15.5 million people were targeted with drug coadministration,with a reported coverage of 82.5% (54.8%to 94.3%). In addition, 35.7 and 52 million people werecovered with DEC alone in 2002 and 2003, respectively.Chapter 3 Programme implementationThe National Filariasis Control Programme was launchedin 1955 to determine the degree of endemicity, to carryout pilot studies and to train the personnel required forIn 2003, a total of about 95 500 drug distributors weretrained and about 1700 people participated in training indisability prevention and control.Table 3.30 Goal: to eliminate LF from India by 2015Objectives• To interrupt transmission of LF• To prevent LF-associated disabilityStrategies• MDA with DEC alone or co-administration of DEC plus albendazole oncea year for a minimum of six years• Foot hygiene through community home-based care by the sufferers ortheir relatives in accordance with WHO guidelines
Page 1 and 2:
For further information about lymph
Page 3:
WHO/CDS/CPE/CEE/2005.52GlobalProgra
Page 7 and 8:
3Report of the Technical Advisory G
Page 9 and 10:
P R O G R A M M E H I G H L I G H T
Page 11:
I N T R O D U C T I O N7This Annual
Page 14 and 15:
10Annual Report on Lymphatic Filari
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 26 and 27:
Page 28 and 29:
Page 30 and 31:
Page 32 and 33:
Page 34 and 35:
Page 36 and 37:
Page 38 and 39:
Page 40 and 41:
Page 42 and 43:
38Figure 3.2 Outcomes and planning
Page 44 and 45:
Page 46 and 47:
Page 48 and 49:
Page 50 and 51:
Page 52 and 53:
Page 54 and 55:
Page 56 and 57:
Page 59 and 60:
UNITED REPUBLIC OF TANZANIA55Endemi
Page 61 and 62:
ZANZIBAR, UNITED REPUBLIC OF TANZAN
Page 63: 59AMERICAN PROGRAMME REVIEWGROUPAt
Page 66 and 67: 62Figure 3.63 Outcomes and planning
Page 68 and 69: 64Annual Report on Lymphatic Filari
Page 86 and 87: 82Figure 3.100 Outcomes and plannin
Page 104 and 105: 100Annual Report on Lymphatic Filar
Page 118 and 119: 114Figure 3.196 Outcomes and planni
Page 127: C H A P T E R 6FURTHER DOCUMENTATIO
Page 135 and 136: ANNUAL REPORT FOR THE NATIONAL PROG
Page 137 and 138: 1332. PROGRAMME RESOURCES2.1 Please
Page 139 and 140: 1353.3 Interruption of transmission
Page 141 and 142: 1373.3.6a Report of MDA coverage by
Page 143 and 144: 1393.3.7 Surveys in sentinel sites
Page 145 and 146: 1413.3.10 Please attach a map of th
Page 147 and 148: 1434. SERIOUS ADVERSE EXPERIENCES (
Page 149 and 150: A N N E X E SANNEX 3: LIST OF LF-EN
Page 151 and 152: 147RAPLOARPRGSAESEAROTAG-LFTDRUNDPU
Page 153 and 154: 149Drug administration and monitori
show all

Global Programme to Eliminate Lymphatic Filariasis ... - libdoc.who.int

Create successful ePaper yourself

Delete template?

Save as template?